Abstract | Increasing numbers of drugs are being developed for the treatment of multiple sclerosis (MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in clinical trials and for monitoring responses to disease-modifying drugs in individual patients. Most outcomes used in trial and clinical settings reflect either clinical or neuroimaging aspects of MS (such as relapse and accrual of disability or the presence of visible inflammation and brain tissue loss, respectively). However, most measures employed in clinical trials to assess treatment effects are not used in routine practice. In clinical trials, the appropriate choice of outcome measures is crucial because the results determine whether a drug is considered effective and therefore worthy of further development; in the clinic, outcome measures can guide treatment decisions, such as choosing a first-line disease-modifying drug or escalating to second-line treatment. This Review discusses clinical, neuroimaging and composite outcome measures for MS, including patient-reported outcome measures, used in both trials and the clinical setting. Its aim is to help clinicians and researchers navigate through the multiple options encountered when choosing an outcome measure. Barriers and limitations that need to be overcome to translate trial outcome measures into the clinical setting are also discussed. NATURE REVIEWS | NEUROLOGY VOLUME 14 | FEBRUARY 2018 | 75 REVIEWS © 2 0 1 8 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
Multiple sclerosis (MS) is a major cause of irreversible disability in young adults. This disability can occur as a consequence of either acute relapses with incomplete recovery or clinical progression independent of the presence of relapses 1 . The pathological processes that lead to the development of acute disability are different from those that contribute to clinical progression. Acute inflammatory demyelination is responsible for the occurrence of relapses, whereas neurodegeneration is the main determinant of progressive disability 2 . Few licensed treatments are available to slow progressive MS, whereas numerous disease-modifying treatments are available to reduce the frequency of relapses in relapsing-remitting MS (RRMS). Consequently, current research efforts are shifting towards the treatment of progressive MS, and the number of trials has increased steadily over the past 5 years.
The appropriate selection of outcome measures is central to assessing the efficacy of novel drugs, which determines whether a drug can be moved to the next step of a drug development programme and thus whether it will obtain regulatory approval. The efficacy of an experimental therapy cannot be demonstrated if the selected measure is unable to capture it, and no trial designs can compensate for the use of inappropriate and poor outcome measures. Outcome measures in RRMS trials focus on clinical (relapse) and radiological (lesion count) markers of inflammation, whereas in progressive MS trials, the emphasis is on measures of clinical progression and brain atrophy as markers of neurodegeneration. However, ideal disease-modifying treatments would prevent both inflammation and neurodegeneration 3 . In the clinical setting, similar outcome measures are used to monitor responses to treatment in individual patients and for decision-making, such as choosing a specific initial disease-modifying agent or escalating to second-line treatment. Although most of the outcome measures used in clinical trials are used in routine practice, technical, financial and logistical issues mean that levels of standardization and quality control are lower in the clinic than in trials. However, important efforts have been made to standardize outcome measures for use in the clinic, especially in relation to the tools used to monitor treatment response, to enable comparisons across centres 4, 5 . The answer to the question, 'What makes an outcome measure appropriate?' is a complex one. The psychometric properties of the measure must be appropriate for the study, and the chosen measure should be reliable and valid. Reliability indicates that the data collected are accurate and reproducible, whereas validity refers to the ability of the tool to measure what it is supposed to measure. In addition, the outcome measure must be responsive; that is, it must be able to detect changes in the specific functions and areas that are expected to occur as a consequence of the intervention or therapy 6 . The degree of the predicted changes in the outcome measure and the period of time within which they are expected to happen are also factors that need to be considered 7 . Well-known, traditional end points used in MS trials have the advantage that they are immediately understood by clinicians, whereas novel outcomes could provide insights into subtle but still relevant treatment effects that would be overlooked by traditional end points. In the clinical setting, the choice of a tool to assess treatment response must additionally take into account ease of use, whether the data collected are clinically useful and whether interpretation of the test results is straightforward.
In this Review, we discuss the advantages and limitations of clinical and imaging outcomes used in MS clinical trials, which need to be considered when interpreting trial results and designing new studies. We particularly focus on composite outcomes, which are increasingly being employed in trials of treatments for progressive MS. The value and practicality of various treatmentresponse measures used in routine clinical practice are also described. Finally, we discuss the complementary roles of subjective and objective outcomes that are considered clinically meaningful from the perspectives of patients and health-care professionals.
Outcomes in clinical trials
In this section, we first describe clinical, neuroimaging and other outcome measures that have been used in clinical trials (especially phase III trials) and then review combined clinical and MRI measures.
Clinical outcomes
Clinical outcomes used in trial settings can be divided into measures of clinical relapse, measures of disability progression and patient-reported outcome measures (PROMs). Relapse-based outcomes are important in RRMS trials, whereas progression-related outcomes are prominent in progressive MS trials. PROMs can be observed in all types of trials. In the past decade, regulatory agencies have shown a growing interest in the use of PROMs to measure common and disabling symptoms such as pain, fatigue and depression in MS trials 8, 9 .
Clinical relapses. The majority of phase III trials have been carried out in patients with RRMS and, to a lesser extent, in people with clinically isolated syndrome (CIS) (FIG. 1) . As the treatments investigated in these trials aim to reduce (or suppress) the inflammatory activity responsible for acute relapses, the most relevant outcome measures relate to relapse (TABLE 1; see Supplementary information S1,S2 (tables)). Relapse-centred outcome measures can be classified into four groups (Supplementary information S1,S2 (tables)): the number of relapses (the simplest and most widely used measure); relapse considered as a binary phenomenon (that is, the proportion or number of patients with versus those without relapse); the time to first relapse while on treatment (a common metric in CIS trials); and composite outcome measures.
Relapse is generally defined as the occurrence of new or recurrent neurological abnormalities that are separated by ≥30 days from the onset of the preceding event, last for ≥24 h and occur without fever or infection 10 . The definition of relapse has changed over time and is becoming increasingly stringent 11, 12 . For example, in the phase III ALLEGRO trial, which compared laquinimod with placebo in RRMS, neurological symptoms had to last for ≥48 h to be considered relapses 12 . The majority of trials mandate an objective diagnosis of relapse, made by the examining neurologist, and supported by pre defined increases in the Expanded Disability Status Scale (EDSS) score and/or its associated functional system subscores [13] [14] [15] . The most widely used outcome measure is the annualized relapse rate (ARR, defined as the number of relapses per patient-year during treatment), which has been used so far in >40 phase III trials, mostly in RRMS (TABLE 1; • Many clinical response measures are used in clinical trials: relapse-derived measures reflect the clinical effect of inflammatory activity, whereas disability-derived measures reflect the effect of neurodegeneration • Among the neuroimaging measures used in clinical trials, lesion-derived metrics capture inflammatory activity, whereas brain atrophy measures reflect neurodegeneration; the choice of measure should reflect the drug's mechanism of action • Owing to technical, financial and logistical barriers, most of the clinical and neuroimaging response measures used in trials are not used in the clinical setting • All clinical and neuroimaging response measures used in the clinic should have a clear meaning at the individual level • Combined (clinical and MRI) outcomes can be used in both trial and clinic settings, although their increased sensitivity to detect treatment effects particularly favours their use in trials • The use of patient-reported outcome measures is important because they capture the impact (and effects) of the intervention on clinical disability, MRI parameters, daily activities and quality of life see Supplementary information S1 (table) ). In more than half of these trials, and in all the RRMS trials, ARR was the primary end point (TABLE 1) . The ARR is easy to understand and compute, and is thought to be a good reflection of the extent of inflammatory activity in MS. However, the ARR might lack specificity with respect to the severity and course of MS, as background levels of disability and the severity of relapse are not captured. This limitation has prompted use of the annualized rate of severe relapses (defined as the number of on-treatment relapses per patient-year that require intravenous steroid treatment and/or hospitalization 12 or that result in a high level of disability 16 ). This measure has been used since 1993 as a secondary end point (TABLE 1) . However, the lack of standardized guidelines for steroid treatment and hospitalization has led to enormous inter-site variability in the management of relapse. This heterogeneity might represent a source of unmeasured bias or confounding that undermines the use of the annualized rate of severe relapse as a clinical end point in multicentre trials.
Relapse-centred binary outcome measures have been used since the very earliest trials in MS and are becoming increasingly popular with the advent of highly effective drugs that enable some patients to achieve relapse-free status. The percentage of relapse-free patients and the percentage of patients with one or more relapses depend on the study duration, as the risk of relapse increases with time; therefore, the study design needs to be considered when comparing the results of trials using these outcome measures. For example, in the GATE phase III trial, generic glatiramer acetate was compared with branded glatiramer acetate and with placebo in patients with RRMS. In this 9-month study, the percentage of relapsefree patients in the placebo group was 79%. By contrast, in RRMS trials of longer durations (usually 24 months), such as FREEDOMS 13 or ALLEGRO 12 , the percentage of relapse-free patients in the placebo group was around 50-60%. This large numerical difference has immediate statistical consequences: to be able to detect a given difference in the proportion of relapse-free patients between the placebo and active-treatment arms, much greater sample sizes are needed if the percentages in both groups are around 50% than if they are closer to 0% or 100%.
The time to first relapse while on treatment is often used in CIS studies because the occurrence of the first relapse after study entry indicates conversion to clinically definite MS (CDMS) [17] [18] [19] ; therefore, time to onset of CDMS is often the primary trial end point in this setting (TABLE 1; see Supplementary information S1 (table) ). Nature Reviews | Neurology primary outcome; the difference in this outcome between the treatment and placebo groups reached statistical significance well before the time to first relapse, which enabled detection of a dose-response effect in REFLEX that was not apparent from clinical outcomes 21 .
The most important composite outcome is time to treatment failure, defined as occurrence of the first confirmed relapse while on treatment, or permanent treatment discontinuation for any cause 14 . This composite primary end point was first introduced in the TENERE study, which compared oral teriflunomide 7 mg and 14 mg versus IFNβ-1a in RRMS 14 (TABLE 1) . This outcome is thought to capture all the factors that determine the effectiveness of a therapy (such as efficacy, safety and tolerability) and therefore is considered applicable to real-life clinical settings.
Measures of disability progression. Measures of disability progression are generally used as primary outcome measures in phase III trials in progressive MS ( 23, 24 , with the exceptions of the ORATORIO study of intravenous ocrelizumab versus placebo in patients with primary progressive MS (PPMS) 25 and the EXPAND trial of oral siponimod versus placebo in secondary progressive MS (SPMS) 26 . Many trials in patients with RRMS or CIS have also included disability progression as a primary or secondary trial end point (TABLE 1; see Supplementary information S1,S2 (tables)), which suggests that targeting clinical progression is also a priority in relapsing forms of MS. Outcomes related to disability progression can be classified into five groups: those that quantify progression as a continuous variable, typically on the basis of the change in the EDSS 27 score or the EDSS score at follow-up; metrics that quantify progression as a binary phenomenon, such as the proportion of patients with or without (confirmed) disability progression; metrics that quantify the (confirmed) improvement in disability as a binary phenomenon; metrics that quantify the time to confirmed disability progression (CDP); and composite outcome measures (TABLE 1) .
The most frequently used outcome measure that quantifies progression as a continuous variable is the absolute change in EDSS score from baseline to follow-up ( and CARE-MS II 29 , changes in EDSS raw scores were reported, but other trials (such as the Copolymer-1 trial in RRMS 30 ) have used the EDSS step methodology instead, which assigns new values to observed EDSS changes depending on the value of the patient's baseline EDSS score. That is, an increase of 1 point in the EDSS score can be considered either as a 1-step change if the baseline EDSS score is below 5.5, or as a 2-step change if the baseline EDSS score is 5.5 or above. This approach is intended to overcome the nonlinear behaviour of the EDSS. The main limitations of EDSS-based outcome measures are that a worsening in EDSS score does not identify the functional system in which the change occurs and that a transient (relapse-associated) functional deficit can lead to a similarly transient change in the EDSS score 31 . Additionally, the EDSS might not be sensitive to deterior ations in upper limb motor function, cognitive function or short-distance walking, which can occur in patients with progressive MS and high baseline EDSS scores 32 . In addition, the absolute change in EDSS score, especially when relying on a small number of visits, might be affected by the low inter-rater and intra-rater reproducibility of the scale, especially in scores at the low end of the scale 33 . The EDSS score also does not reflect the patient's overall functional impairment, as this score has a low ability to discriminate between people with different levels of disability according to the Barthel index 34 (a measure of functional independence in ten daily activities 35 ). Therefore, changes from baseline in scores other than the EDSS, such as the MS Functional Composite (MSFC) 36 and its subtests 37, 38 , such as Regional Functional System Score (RFSS), ambulation index, arm index and cognitive tests 39, 40 , have been included in some trials to complement the EDSS ( 41 . For the PASAT, changes in the z-score over the trial period were used 42, 43 . For BRB-N, different trials have used different outcome measures: the phase III North American trial of subcutaneous IFNβ-1b in SPMS used the change in a composite neuropsychological score as an end point 40 , whereas in the ARIANNA study (atorvastatin add-on versus placebo add-on in patients with RRMS also receiving subcutaneous IFNβ-1b), the outcome measure was the change in the percentage of patients with mild or severe cognitive impairment, which was defined as failure in 1-2 versus ≥3 tests, respectively 39 . Outcomes relating to progression, whether as a binary phenomenon (the proportion of patients with or without CDP) or as the time to CDP, are numerous and vary considerably between studies (TABLE 1; see Supplementary  information S3 (table) ). CDP is defined as a worsening of the EDSS score (usually by 1.5 points when the starting EDSS is 0, by 1.0 point for starting EDSS scores ≤5.5 and by 0.5 points for starting EDSS scores >5.5) that persists for either 3 months or 6 months. However, 3-month CDP and 6-month CDP both overestimate the long-term accrual of irreversible disability (by 30% and 26%, respectively) 44 . Longer assessment periods, although not completely free from such bias (12-month CDP and 24-month CDP still overestimate the long-term accrual of irreversible disability but by only 20% and 11%, respectively), are recommended to assess the accrual of truly irreversible disability, with a possible but small positive effect on the sensitivity of the progression criteria 44 . However, so far, no trials have used such long CDP periods. Most trials have used both 3-month and 6-month CDP, although some studies (notably, CARE-MS I 28 and CARE-MS II 29 ) used only 6-month CDP. Trials using either the time to 3-month CDP or the percentage of patients with 3-month CDP as the primary end point tend to include the time to 6-month CDP as a secondary end point.
The MSFC or its subtests (25 ft Timed Walk Test (TWT), 9-Hole Peg Test (9HPT) and PASAT) 38 
can be used instead of EDSS scores to define CDP. Although training effects are often seen in PASAT scores, which could theoretically be responsible for the reduced responsiveness of the MSFC versus that of the EDSS 45 , this suggestion is not supported by the results of the trials published so far, in which MSFC-derived outcomes seem to be more sensitive than EDSS-derived outcomes to disability progression. For example, the CARE-MS II 29 and FREEDOMS II 46 trials in RRMS as well as the IMPACT trial in SPMS 42 all reported statistically significant between-group differences in MSFC-based outcomes but not in EDSS-based outcomes. Moreover, trials that reported significant between-group differences in EDSS scores, such as CARE-MS I 28 and FREEDOMS 13 , also tended to show significant between-group differences in MSFC-derived outcomes.
Further attempts have been made to improve the sensitivity of MSFC and its subtests to disease progression and thereby to increase its sensitivity to treatment-related effects. For instance, some researchers have suggested that increases of only ≥20% in MSFC subtest scores are clinically meaningful and have an acceptable signal-to-noise ratio, suggesting that clinical trials should use this 20% cut-off to define binary outcome measures that are based on MSFC subtests 47 . However, so far, only one phase III trial -the ARIANNA study, which compared oral atorvastatin add-on with subcutaneous IFNβ-1b in patients with RRMS -has done so 39 . Nevertheless, despite the increased sensitivity of this MSFC-derived outcome measure, the trial yielded negative results.
Among the outcome measures based on improvement in CDP as a binary phenomenon, the most widely used are based on sustained improvement in the EDSS score, which was used as a secondary outcome in CARE-MS II 29 and the Copolymer 1 MS study 30 (TABLE 1) . This outcome measure has been used only in phase III treatment trials in RRMS, possibly reflecting the role of acute inflammation in the development of disability in this setting. A phase II study of biotin in patients with progressive MS also used improvement in disability as the primary outcome measure 48 . In this study, which showed positive results, the improvement in CDP was reflected by improvements not only in EDSS scores but also in TWT scores 48 . Improvement was defined as a decrease in EDSS scores of ≥0.5 points for baseline scores of 6-7 points or ≥1.0 point for baseline scores of 4.5-5.5 points or a ≥20% decrease in TWT time. Sustained improvement in disability as an outcome measure might therefore reflect clinical changes secondary to not only remission of inflammation but also tissue regeneration, which might be expected to occur with the new investigational drugs for progressive MS, such as biotin 48 , simvastatin (tested in the phase II MS-STAT trial 49 ) and oxcarbazepine (currently being tested in the phase II PROXIMUS trial 50 ). Composite end points for progression result in higher event rates than single measures, which theoretically increases the sensitivity of the parameter, thereby reducing the duration of the trial and the sample size required to detect a difference between the groups. In addition, composite end points theoretically reduce the risk of multiplicity and thus the risk of type I errors (false-positive findings), which can lead to erroneous claims of efficacy for investigational treatments, especially if only positive results are reported 8 . For example, if statistical tests are independently performed on six subgroups, each at a significance level of 2.5%, the chance (P) of finding at least one false-positive statistically significant test result is 1 -(1 -0.025) = 14% 6 . Therefore, composite end points should be prespecified before starting the trial, and their individual components should be analysed only when a statistically significant treatment effect is found for the composite, unless the components have also been prespecified as outcome measures 8 . A re-analysis of data from a PPMS trial showed that the use of composite end points including different disability measures improved the detection of treatment effects and reduced the sample size needed for clinical trials 51 . The highest efficiency and event rate estimates were obtained by using a sustained disability progression end point confirmed by any two of the following parameter pairs: EDSS and TWT; EDSS and 9HPT; or TWT and 9HPT. This composite end point usefully employs the Boolean operator 'and/or' , which maximizes the likelihood of detecting a clinical event. However, composite end points are valid only when they include outcomes that are causally related to the treatment 52 . A phase III trial in PPMS used as the primary outcome measure the time to 3-month CDP, derived from a composite end point defined as the presence of at least one of the following changes: increase in EDSS (of 1 point if baseline EDSS was <5.5 or of 0.5 points if baseline EDSS was ≥5.5); ≥20% increase in 9HPT; and ≥20% increase in TWT 53 . Other post hoc re-analyses of trial data have suggested that this composite end point can distinguish patients with MS who experience ongoing progression from those with stable disease 53 and thereby represents an appropriate end point for disability progression trials. Another composite outcome used as a secondary end point in one SPMS trial 54 is the time to 3-month CDP or treatment failure, which was defined as a confirmed 20% increase in 9HPT (Supplementary information S3 (table) ).
Patient-reported outcome measures. Patient-completed questionnaires are used to assess the influence of MS on daily activities, social functioning and quality of life. In 2009, the FDA published guidance on PROMs 8 , which were defined as "any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else" (REF. 8 ). In 2016, the EMA defined PROMs as any data directly reported by a patient that are based on his or her perception of a disease and its treatment, thereby further developing the concept of 'personal perspective' . PROM is an umbrella term that includes evalu ations of symptoms, health-related quality of life, health status, well-being, satisfaction with treatment and adherence to treatment. Therefore, PROMs complement and support outcome measures based on clinical assessments and (as mentioned in the FDA guidance document 8 ) can be used in clinical trials to measure the harms associated with a given treatment as well as its benefits 8, 55 . PROMs can be either condition-specific or generic. Condition-specific PROMS designed for patients with MS cannot be extrapolated to the general population and are sensitive enough to detect MS-induced changes. Examples of MS-specific health-related quality of life PROMs are the 29-item MS Impact Scale (MSIS-29) 56 , Patient-Reported Indices in MS (PRIMUS) 57 and MS Quality of Life-54 (REF. 58 ). Of the 13 fatigue-centred PROMs proposed in the past 20 years, the most popular are the Fatigue Severity Scale (FSS) 59 and Fatigue Impact Scale (FIS) 60 (TABLE 2) . MS-specific PROMs that measure the impact of motor impairment on daily activity, such as the arm index 36 and the MS Walking Scale (MSWS-12) 61, 62 , have been frequently used as trial end points in the past 5 years 53, 63, 64 (TABLE 2) . A reduction of 4-6 points on the MSWS-12 is considered clinically meaningful 65 , although the MSWS-12 has also been used as a continuous measure of symptom improvement (that is, without applying any specific thresholds) in the fampridine trial 66 . Many generic PROMs (particularly those that focus on symptoms such as pain, tremor and spasticity) have also been used in MS trials 67, 68 , but a deep discussion of these measures is outside the scope of this Review.
A PROM that in the future might be further studied and validated for use in clinical trials and clinical practice is the patient-determined disease step (PDDS), which is simple and economical to apply compared with the EDSS and correlates positively with both the EDSS itself and its functional system scores 69 as well as with subscales of both the modified FIS (MFIS) and MSIS-29. One trial included the physical subscale of the MSIS-29 as a joint primary end point of the study alongside the EDSS-based time to 6-month CDP 64 . Composite end points can usefully be obtained by combining objective measures (such as the EDSS) and subjective PROMs, although the limitations associated with composite end points already discussed above will similarly apply to combined end points that include PROMs. (table) ). The most commonly used MRI measures are based on T1 gadolinium-enhancing and new T2 brain lesions, which reflect the occurrence of new inflammatory activity. In particular, gadolinium enhancement signifies breakdown of the blood-brain barrier as a consequence of acute inflammation in the CNS. However, the fundamental difference between T1 gadolinium-enhancing and new T2 brain lesions is that gadolinium-enhancing lesions are transient (average duration 3 weeks 71 ); consequently, a single scan will not capture a cumulative increase in inflammation over time. Owing to the (generally) non-transient nature of T2 lesions, the appearance of new T2 lesions since the previous scan does capture the cumulative new inflammation occurring in the interval between scans. Nonetheless, the number of gadolinium-enhancing lesions at a given point during follow-up or at the end of follow-up is the most widely used MRI outcome in all phase III trials (TABLE 3) . T1 hypointense lesions are visible during both the acute phase of lesion development (when they correspond to lesional oedema) and the chronic phase 72, 73 (when they are called permanent black holes and are mostly used as a post hoc measure of tissue destruction and recovery) 12 . Lesion-derived measures can be divided into three categories: outcomes that measure the occurrence of new lesional activity during a given period, such as the number of new and/or enlarging T2 lesions or new T1 gadolinium-enhancing lesions; outcomes that quantify the T2 hyperintense, T1 hypointense or gadoliniumenhancing total lesion volume; and outcomes that estimate inflammatory activity as a binary phenomenon, such as the proportion of patients with or without gadolinium-enhancing lesions. Composite MRI measures could also be included within the group of outcomes that measure new acute lesional activity. For example, the number of combined unique active (CUA) lesions is defined as all new or enlarging T2 lesions or new gadolinium-enhancing lesions, provided that the same focal lesion is counted only once. This end point describes the total number of active lesions in the widest sense and was already used in the first clinical trials in RRMS. In CIS trials, the number of CUA lesions was used for the first time in the ETOMS study 74 , and in SPMS trials, it was first used in the SPECTRIMS study 75, 76 . So far, at least 13 phase III trials have used the number of CUA lesions as an end point (TABLE 3) .
Neuroimaging outcomes
The greatest advantage of lesion-related MRI markers is that they provide objective measures of the underlying MS pathology and correlate with clinical outcomes in RRMS, in particular, with relapse, at least in the short and medium terms 77 . Over 80% of the between-trial vari ability in treatment effects on relapse is explained by the variability in treatment effects on new T2 lesions 78 . In addition, treatment effects on relapse in phase III trials can be predicted by treatment effects on lesion-related MRI outcome measures in the corresponding phase II trials of the same drug 79 . Another advantage of lesionrelated MRI measures is their high sensitivity, which enables the efficacy of two active drugs to be directly compared, which can otherwise be difficult when the outcome is clinical relapses. For instance, in the GATE study, which compared generic glatiramer acetate with the original branded drug, lesion-related MRI outcomes were used to show the equivalence of the two drugs 80 . Identification of new T2 lesions can be hampered by factors such as a high pre-existing lesion load, suboptimal repositioning of serial scans and poor inter-observer reproducibility. Image subtraction can overcome these issues by providing good visualization and quantification of both active and shrunken or resolved T2 lesions 81 . The combination of automated identification of new or enlarging lesions with automated image subtraction protocols might be useful to improve the cost-effectiveness of MRI and reduce the risk of adverse events associated with gadolinium administration 82 .
Brain atrophy measures.
The rationale for the use of brain atrophy measures in clinical trials is that atrophy reflects neurodegeneration, which is the pathological process most consistently linked to accrual of disability [83] [84] [85] . Metrics derived from brain volume can be divided into those that calculate global brain atrophy as either brain parenchymal volume 86 or fraction 39 (that is, the ratio of brain parenchymal volume to the total volume within the brain surface contour) and their change over time and metrics that estimate regional volumes, such as white matter and grey matter, and changes therein during the trial 87 (TABLE 3; see Supplementary information S5,S6 (tables)).
In RRMS, the effect of treatment on brain atrophy correlates with the effect on disability progression over 2 years, and is independent of the effect on active MRI lesions 66 . Total brain volume and fractional volume are the non-lesional outcome measures most commonly used in phase III trials in this setting (TABLE 3) . Total brain volume or fraction is generally used as a secondary outcome measure in phase II and III RRMS trials, such as FREEDOMS 13 , where fingolimod was compared with placebo, or CARE-MS I 28 and CARE-MS II 29 , where alemtuzumab was compared with IFNβ-1a.
The two most widely used measures of global brain atrophy are the brain parenchymal fraction, a segmentation-based technique that reduces the variability caused by individual variation in brain size and has high testretest reproducibility when compared with raw brain volume 88 , and the percentage brain volume change (PBVC), which is calculated from a registration-based difference map of brain contours over time 89, 90 . Brain parenchymal fraction was used in the phase II trial of natalizumab in RRMS 91 and the phase II trial of IFNβ-1b in PPMS 92 ; PBVC was used in the phase III fingolimod trials (TRANSFORMS 93 , FREEDOMS I 13 and FREEDOMS II 46 ) and phase III laquinimod trials (BRAVO 94 and ALLEGRO 12 ). PBVC was used for the first time as a primary end point in a phase II 49 trial in SPMS 95 and also in the ongoing phase II ARPEGGIO trial in PPMS 96 . Several technical sources of MRI measurement errors are well-known, such as changes in magnet, gradients, coils, distortion corrections and image-contrast parameters that affect tissue segmentation. In addition, measures of global brain atrophy are susceptible to several specific sources of error. The phenomenon of pseudoatrophy is probably due to resolution of inflammation and oedema and is seen especially in patients receiving active treatment who have a high gadolinium-enhancing lesion volume at baseline 97, 98 . Other sources of error are physio logical (circadian) variations in hydration status 99 and cardiovascular risk factors (particularly smoking), which are associated with reduced brain volume 100 . The regional volume measures most commonly used quantify grey matter and white matter changes. The change in the volume of cerebrospinal fluid (CSF), normalized by the total intracranial volume, has also been used in some phase III trials 101, 102 to indirectly quantify the loss of neural tissue. A single phase II trial used the partial (central) cerebral volume, a surrogate estimate of global atrophy 87 . This same trial also showed that the reduction in grey matter volume over time is greater than that in the white matter and is less affected by pseudo-atrophy 98 , as other observational studies have also reported 103 . Grey matter and thalamic volumes were used as additional outcome measures in the phase III ALLEGRO study 12 . If these regional volume measures are confirmed to show greater changes over time than is seen in global atrophy measures 87, 104, 105 , use of regional volume measures will result in increased sensitivity and enable smaller sample sizes to be used.
Spinal cord atrophy.
The rate of brain atrophy in MS is approximately 0.5% per year 106 , which is lower than the rate of spinal cord atrophy (up to 2.2% per year in SPMS 107 ), suggesting that spinal cord atrophy is a sensitive and meaningful marker of neurodegeneration. Spinal cord atrophy is usually measured at the cervical level and is associated with long-term development of motor disability in not only progressive MS 107 but also CIS and RRMS 108 . Trials in PPMS or SPMS have used the change in cord area 53 as a secondary end point (Supplementary information S7 (table) ). However, methodological factors can affect the accuracy of this measurement, mostly noise related to cord movement and the limited spatial resolution of current MRI scanners relative to the small cord size. Additionally, spinal cord atrophy-related measures are calculated using semi-automated segmentation-based methods, which are subject to inter-rater variability. These issues imply that larger sample sizes are needed for multicentre trials than for trials conducted at a single centre or using a single scanner 109 .
Novel imaging outcomes for neurodegeneration and remyelination. Various outcomes have been used over the past 5 years to detect the effect of drugs on the CNS at a microscopic level. The advantage of such measures is that they are expected to be more tissue-specific than conventional MRI measures for the underlying pathophysiological processes and therefore might detect subtle changes not observable by conventional MRI. These novel measures could provide complementary information to that given by conventional imaging end points and might offer insights into the mechanism of action of experimental medications as well as into the mechanisms of any treatment-related adverse effects.
The most widely used measure is the magnetization transfer ratio (MTR) in the whole brain 12, 15, 110 (TABLE 3;  see Supplementary information S4 (table) ). MTR changes are thought to reflect the processes of demyelination 111 and remyelination 112 . Apart from whole-brain MTR, regional MTR measures (including grey matter, white matter and lesional MTR) have been used, for example, in the phase III ALLEGRO trial in RRMS 12 . Other measures used -mostly in the past -to show an effect of disease-modifying treatments include concentrations of metabolites such as N-acetyl aspartate, estimated by magnetic resonance spectroscopy 12, 113 . Novel secondary outcome measures currently used in phase II trials in SPMS include diffusion parameters derived from neurite orientation dispersion and density imaging, which estimate the microstructural complexity of dendrites and axons in vivo 114 , and sodium imaging 95, 115 , which reflects neuronal damage and possibly mitochondrial dysfunction 116 . Optical coherence tomography (OCT) measures axonal and neuronal loss within the anterior visual pathway, which correlates with not only visual function 117, 118 but also whole-brain processes of neurodegeneration, especially in patients with progressive MS 119 . For this reason, OCT measures of neuronal loss have been proposed as outcome measures in clinical trials in both optic neuritis 120 and non-optic neuritis MS, such as PROXIMUS (add-on oral oxcarbazepine versus placebo in progressive MS) 50 , FLUOX-PMS (oral fluoxetine monotherapy versus placebo in progressive MS) 121 and ACTiMuS (bone-marrow-derived cellular therapy in progressive MS) 122 . BOX 2 and Supplementary information S8 (table) provide further details on OCT-related outcome measures. In that study, the authors compared different criteria defining treatment response and found that the one with the best accuracy was a combined outcome measure -thus, the absence of relapse and disability, in conjunction with inflammatory activity below specific MRI-based thresholds after a given time on treatment, indicated a negligible risk of progression over further follow-up 4 . A first attempt at predefining an outcome measure for the absence of disease activity was made in the natalizumab AFFIRM trial 123 . Initially termed 'disease activity freedom' , this measure was redefined in 2014 as 'no evidence of disease activity' (NEDA) 3 , meaning no relapses, no progression of disability and no MRI activity (new or enlarging T2 lesions or T1
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Box 2 | Potential future outcome measures in MS Clinical
Wearable sensors -portable electronic devices attached to the body that record information about the user's quantity and quality of movement -are being developed, mainly for use in the clinic. This 'smart' technology can provide objective and quantitative data 165 to evaluate responses to therapeutic interventions in real-life situations. Several strategies have been developed to maximize the sensitivity of current disability scores to disease progression, for example, by re-baselining the Expanded Disability Status Scale (EDSS) score (that is, by using scores at both screening and baseline visits rather than only the baseline score to determine what the first EDSS score was for that patient) and by using new metrics such as the area under the curve described by EDSS score trajectories over time 131 .
Imaging
PET markers of remyelination (such as within-lesion magnetization transfer ratio 166 or the level of binding of 11 C-labelled Pittsburgh compound B 167 ), chronic inflammation (such as the presence of slowly enlarging lesions 168 ) and microglial activation (the level of binding of translocator protein [169] [170] [171] ) could bring us closer to achieving precision medicine 170 . Advanced optical coherence tomography (OCT) techniques provide quantitative measurements of both axonal (retinal nerve fibre layer) and neuronal (ganglion cell layer) loss in vivo, which represent an ideal model for assessing the neuroprotective effects of novel agents 118 . Possible advantages of including OCT outcomes in clinical trials are that changes in the retinal structure might predict not only the clinical response to treatment 172 but also the risk of developing specific ocular adverse effects 173 .
Neurophysiological
Visual evoked potentials (VEPs) and multimodal evoked potentials (MEPs) have some ability to predict clinical evolution in patients with multiple sclerosis (MS) [174] [175] [176] . The change in full-field VEP latency at week 24 has been used as the primary outcome measure in a phase II trial assessing the efficacy of a remyelinating therapy after the first episode of optic neuritis 177 . gadolinium-enhancing lesions). NEDA has since been used in several phase II 124, 125 and phase III trials (TABLE 3;  see Supplementary information S1 (table)) 28, 29, 101 . NEDA has also been used to compare the efficacy of medications tested in different trials; for example, a greater proportion of patients attain NEDA status in trials of autologous haematopoietic stem cell transplantation (AHSCT) than in trials of other treatments 126 . Because brain volume loss reflects neurodegeneration (the main determinant of progressive disability), some researchers propose that the definition of NEDA should be updated by incorporating the absence of brain volume loss as well as the absence of relapses, MRI disease activity and clinical progression (so-called NEDA-4) 127 .
Another combined end point used in AHSCT trials is event-free survival 128 . Death is included in this end point as a relevant outcome in addition to worsening of disability, relapse and new MRI lesions. This approach suggests that combined measures can be designed to reflect the expected efficacy and main adverse events of a given treatment.
The main objections to the use of composite outcome measures in clinical trials are that the net effect of the experimental drug on the composite outcome can be difficult to interpret if its effect on the individual components differs, and there is uncertainty with respect to the clinical relevance of the outcome for individual patients 52, 129 .
Outcomes in the clinical setting
In this section, we describe clinical and neuroimaging measures that are currently used in the clinic.
Clinical measures
In the clinic, the most widely used clinical measures are related to the occurrence of relapses and to clinical progression, which is generally measured with the EDSS.
Relapse. The number of relapses occurring within a given time frame, usually 6-12 months, is the outcome most commonly used in the clinic. Evaluating relapse traditionally required taking a medical history (which could be associated with recall bias) and inspecting case notes. The use of high-quality prospectively designed databases can improve the retrieval of relapse-related data in the clinic, successfully enabling clinicians to assess treatment effects in clinical practice 130, 131 . The presence of relapses during treatment, in combination with other factors (such as EDSS score increases 4 or MRI disease activity 132 ), has been considered a surrogate for future disability. Along these lines, a study from the MRI in MS (MAGNIMS) group that included 1,280 patients with RRMS receiving disease-modifying treatment showed that the presence of ≥2 relapses (or 1 relapse and ≥3 new T2 lesions) during the first year of treatment with IFNβ was associated with a 29% risk of EDSS score worsening over 3 years as well as a 48% risk of treatment failure, defined as a confirmed EDSS score worsening (a ≥1 point increase in EDSS score if the baseline score was <5.5 or a ≥0.5 increase if the baseline score was ≥5.5) or a switch to other therapies for reasons of lack of efficacy 133 .
Measures of disability. The most widely used clinical measure of disability is the EDSS, which is used in outpatient clinics to assess the severity of clinical relapses and to monitor treatment effects. This scale is based on the standard neurological examination that forms part of any clinical assessment. Clinicians are very familiar with the meaning of scores >4.0, which are based on walking ability. Therefore, EDSS score changes are considered easy to interpret. However, as mentioned above, this tool has low intra-rater and inter-rater reproducibility, especially for patients with mild to moderate disability. Besides, the EDSS is not sensitive to important aspects of clinical progression, such as cognitive dysfunction.
The MSFC is not used as frequently as the EDSS, either in the clinic or in clinical trials. One of the MSFC subtests, the PASAT 134, 135 , assesses the speed of (auditory) information processing and calculation ability and might compensate for the fact that cognitive impairment is not captured by the EDSS. The TWT can be routinely performed in the clinic, for example, to assess an individual patient's ability to walk before and after initiation of fampridine treatment, and thereby determine whether the patient has benefited from the drug 136 . However, the MSFC and its subtests were actually designed to be used for group analyses in clinical trials, rather than in the clinic 38 . Thus, the appropriate use of the MSFC or its components requires an a priori definition of clinically meaningful change. Additionally, the choice of reference population affects the values of MSFC z-scores, which means that they cannot be easily interpreted in the clinic. Other limitations include practice effects 137, 138 , which can influence PASAT results, and the fact that the PASAT can be stressful for patients 139 .
Considering the high prevalence of cognitive dysfunction in the MS population and the substantial impact of this comorbidity on patients' day-to-day lives, a committee of experts on cognitive dysfunction in MS agreed on the need for regular cognitive assessments in patients with MS and proposed a brief battery to be administered in the clinic: the Brief International Cognitive Assessment for MS (BICAMS) 140 . In addition to the Symbol Digit Modalities Test (SDMT) 141 , which measures attention and speed of information processing, BICAMS includes the California Verbal Learning Test (second edition) and Brief Visuospatial Memory Test (revised version) 140 . The SDMT is the most widely used cognitive test and is also included in the BRB-N 142 . Low SDMT scores are associated with increased severity of white matter damage 143 . The SDMT gives more consistent results than the PASAT and is more reliable, in part because it is less stressful than the PASAT 144 . The SDMT requires a total of only a few minutes to perform, and the person administering the test does not require specific training 142 . For all these reasons, the SDMT is considered the best test to be administered if the time allocated to cognitive assessment is strictly limited 140 . Apart from the SDMT and PASAT, the remainder of the tests included in the BRB-N can also be used in the clinic, although training is required for the health professionals administering the test 142 . Finally, the CogState battery (a computerized tool consisting of simple and rapid tests that measure processing speed, attention, working memory, executive function and verbal learning) has been used in several neurological conditions, including MS 145 . In general, cognitive tests are difficult to administer in the clinic owing to time constraints. Thus, self-administered online batteries such as the CogState are promising options for use in clinical practice. Additionally, the CogState uses visual and verbal stimuli that are independent of language and culture and therefore might be preferable to tests that could be influenced by the patient's educational level. Additional factors to consider are the effects of depression, anxiety and fatigue on test performance.
The PROMs discussed above can also be used in the clinic, particularly the fatigue scales, such as the FSS 59 , the MFIS 146 or the visual analogue scale for fatigue 147 . Other useful PROMs are those that relate to depression, anxiety, pain or quality of life. Interestingly, the usefulness of PROMs in the clinic could substantially increase in the near future with advances in technology: PROM-related information could be both collected and displayed to clinicians electronically.
Neuroimaging measures
In this section, we first review the role of T2 lesions, which are still the most commonly used measure of treatment response in the clinical setting. Emerging response measures based on brain atrophy and combined outcomes are also discussed.
Lesion-related measures. MRI has become a vital tool in clinical practice. According to international recommendations, patients with MS should be scanned regularly, usually at least once a year 148, 149 , especially if they are on treatment. Patients receiving immunosuppressive treatments (such as natalizumab, fingolimod or dimethyl fumarate), who have an increased risk of John Cunningham virus (JCV)-positive progressive multifocal leukoencephalopathy, are recommended to be scanned even more frequently 150 . However, other scanning intervals are possible, and the optimal frequency for routine, non-urgent MRI scans in patients with MS is not fully clear 148, 151 . International consensus recommends that brain and/or spinal cord MRI should also be performed when unexpected or atypical symptoms appear 148, 151 . Ideally, when brain MRI is used to monitor disease activity and treatment response, scanning should be performed using the same machine and imaging protocol (that is, the same pulse sequences and spatial resolution) as the reference (baseline) scan 148 .
The most common response measure is the number of new or enlarging T2 lesions in the current scan compared with the previous scan, which is also referred to as the number of active T2 lesions 148 . The number of active lesions is useful to monitor treatment response, as the presence of new T2 lesions while on treatment has been associated with worse clinical outcomes 5, 148 and might indicate the need for a change in treatment 5 .
The development of at least three new T2 lesions in the first year of IFNβ therapy was associated with a 27% risk of treatment failure (defined as a confirmed increase in EDSS score or switching to other therapies for lack of response) and a 22% risk of EDSS worsening over 3 years 133 . A disadvantage of using the number of active T2 lesions as a response measure in the clinic is that the comparison requires both an experienced radiologist and previous MRI scans of the patient to be available. The feasibility and reliability of automated lesion segmentation algorithms are undergoing assessment, and these algorithms are showing promise for the assessment of clinically acquired scans 152 . In the near future, these algorithms could enable the automatic computation of total T2-lesion load in the clinic, which would improve the monitoring of patients with MS.
Another MRI measure used in the clinic is the number of gadolinium-enhancing lesions, which provides information on acute inflammation and does not require the availability of previous MRI scans. The predictive value of gadolinium-enhancing lesions seems to be equivalent to that of the presence of active T2 lesions 148 . Over extended periods of observation, however, the number of new T2 lesions might be preferable to the number of gadolinium-enhancing lesions for the detection of subclinical disease activity, as gadoliniumenhancing lesions represent disease activity in only the immediately preceding 3-6 weeks 71, 153 . Other reasons for preferring T2-related over enhancement-related measures include the increased costs associated with gadolinium use and the fact that gadolinium infusions entail a risk of rare but severe adverse events. The most serious gadolinium-related adverse effect is nephrogenic systemic fibrosis, although the level of risk depends on the specific contrast medium used 154 . Gadolinium can also be deposited in the brain 155 , and the clinical consequences of this deposition remain unknown. Gadolinium administration is not recommended for use in routine MRI safety monitoring of patients receiving natalizumab 156 .
Brain atrophy and other MRI measures. The use of brain measures of atrophy in the clinic is currently controversial [157] [158] [159] . Although the contribution of brain atrophy to clinical and cognitive deficits is well established at a group level 148 , several factors might limit the application of atrophy measures in the clinical setting: the lack of normative values (that is, brain volume changes in healthy age-matched individuals) for patients with MS; intra-individual variability due to physiological variations in brain volume (for example, owing to dehydra tion or alcohol consumption); and the presence of comorbidities or MS-related factors, such as the initiation of disease-modifying treatment (which can induce pseudo-atrophy) 97, 103, 148 . Several techniques -such as Jacobian integration using T1-weighted images 160 and lateral ventricle volume estimation using T2-weighted images 161 -are currently being developed to improve the reliability of atrophy metrics in the clinic. Finally, an important factor to bear in mind is that differences in the MRI hardware and software packages used for image analysis or processing can generate variability in brain atrophy measures 148 . Additionally, MRI scanner upgrades or replacements can render the images acquired at different time points difficult to compare accurately 162 . Ideally, of course, each patient with MS should be scanned using the same scanner and the same protocol whenever possible.
Combined clinical and MRI measures. As discussed above, the results of the MAGNIMS study showed that combining MRI activity with clinical relapses during the first year of IFNβ treatment could identify patients who have a high risk of treatment failure and EDSS score worsening in the short term 133 . In fact, escalation from first-line disease-modifying treatment to a second-line disease-modifying agent is routinely advised in the clinical setting for patients with clinical and radiological evidence of disease activity.
No strong evidence supports the use of NEDA in clinical practice. In 2015, a longitudinal study of 219 patients with MS reported that those who maintained NEDA for 2 years had a very high probability (78.3%) of not showing any disability progression (defined as an increase in EDSS score of >0.5 points) at 7 years of follow-up. However, in 2016, an observational study of 517 consecutive patients with MS found that achieving NEDA after the first 2 years of follow-up was not associated with an improved prognosis at 10 years of follow-up 163 . Although the 2016 study involved a heterogeneous cohort, in which not all patients were on treatment, NEDA might not be a useful measure to predict long-term outcome. In fact, despite its high positive predictive value, NEDA probably has a low negative predictive value. Thus, the failure to maintain NEDA during follow-up does not necessarily imply a substantially worsened prognosis; however, maintaining NEDA is definitely a good prognostic marker. The implementation of NEDA-4 (which includes brain atrophy) in the clinical setting is associated with the same limitations as described for NEDA and has not been validated for use in individual patients.
Translation from trials to the clinic Importantly, in both clinical trials and the clinical setting, outcomes must reflect relevant functional, structural or pathological aspects of the condition and must be reproducible. As already discussed, if outcome measures from clinical trials are used in routine practice, their use is restricted and simplified. This situation has emerged because in clinical trials, these measures are used for investigating treatment effects at the popu lation level, whereas in the clinical setting, they are employed to assess individual patient's responses to treatment, to monitor disease progression or to guide treatment decisions. Thus, although translation to the clinical setting of trial outcome measures used to demonstrate the effects of a drug on patients is desirable, clinical practice must take into account considerations beyond treatment efficacy that also influence patient management, such as the patient's perception of risks and the patient's priorities. In this section, we compare the outcomes used in clinical trials versus those used in the clinic. The strengths and weaknesses of clinical and neuroimaging outcomes used in clinical trials are summarized in TABLES 4, 5. In clinical trials, the clinical and MRI outcomes chosen do not need to be meaningful at the individual level as long as they are meaningful at the group level. For example, the change in MSFC z-score is an outcome that is meaningful at only the group level, and its usefulness stems from comparisons between different treatment groups. In particular, an increase of ≥20% in MSFC z-score or any of its subscores is a clinically relevant increase 47 . Clinical or MRI outcome measures used in clinical trials must also be sensitive enough to detect subtle, though highly relevant, treatmentinduced changes. This high sensitivity is especially important when the trial aims to compare a new drug not with placebo but with another active drug 38 . In clinical trials, the selection of outcome measures that are adequately specific but insufficiently sensitive confers a high risk of a false-negative result, which ultimately implies that a potentially efficacious drug might never obtain approval. By contrast, any type of monitoring instrument (or response measure) used in the clinic must offer meaningful information at the individual level and should probably be more specific than sensitive, as prematurely (or incorrectly) starting or stopping a drug could have harmful consequences for the patient.
Regarding combined outcomes, which have been so extensively and successfully used in clinical trials, their implementation in the clinic will again depend on their meaningfulness at the individual level. Some combined outcomes, such as NEDA, have so far mainly been used in trials, although they could be valid at the individual level and used in the clinic. In fact, when the first attempts were made to define treatment response 4 , the underlying concepts were the same as those underpinning the definition of NEDA, although treatment response required a less-restrictive threshold.
In relation to PROMs, implementation in the clinic might be hampered by high inter-patient and intrapatient variability. In clinical trials, this high variability can be compensated for by large sample sizes. Further limitations restrict the use of PROMs in the clinic: they can be time-consuming to administer; despite the very large number of available measuring tools, clear evidence of superiority of one over the others is lacking; and the large amount of information produced needs to be interpreted and turned into useful data.
Another notable difference between clinical trials and the clinic is the trend towards the use of increasing numbers of outcomes in clinical trials over time (FIG. 1b) . This trend is not evident in the clinic, where the EDSS score has been dominant for a long time. Interestingly, this increase in the number of trial end points is accompanied by an increase in the number of participants per trial (FIG. 1c) , which together might represent an attempt to increase the power of the trial to detect a treatment effect without prolonging the trial duration (FIG. 1d) .
Finally, we need to acknowledge that patients and clinicians might have different perspectives on what outcomes are relevant and desirable. For example, a comparison of the judgements of patients and clinicians as to which domains of health in the short form questionnaire (SF-36) are most important to individuals with MS showed that the patients tend to prioritize general health and vitality, mental health and emotional role limitation, whereas the clinicians thought that physical disability, bodily pain and social function would be the most important considerations for the patient 164 . Undoubtedly, these factors also need to be taken into account when translating outcomes from trial settings to the clinic. Ultimately, holistic approaches that accommodate both patients' and clinicians' priorities are probably preferable in the clinical setting, whereas these factors might not be a priority in clinical trials. Higher sensitivity than individual components for detection of disability progression, implying smaller sample sizes or trial durations needed (T); reduced risk of type I error (T); NEDA is a comprehensive measure of real-life treatment effect (B)
Individual components cannot be analysed independently unless they were predefined as outcome measures (T); composite outcomes must include measures causally related to treatment (T)
PROMs
All PROMs (B) Information comes directly from the patient (B) Information is subjective and can fluctuate within individuals (B) 
Conclusions
Over a dozen agents that can reduce the inflammatory component of MS are now available, but an unmet and urgent need remains for agents that can treat progressive MS and promote tissue repair and neuroprotection. The availability of clinical and imaging outcome measures suitable for use in trials of such agents is of the utmost importance to ensure the detection of drug efficacy -and is nowhere more needed than in phase II trials of agents to prevent or slow progression. The choice of the best set of outcomes for a given trial can be difficult because of the large number of possible response measures described and used in the literature. However, some guiding principles can be derived. All trials should include clinical measures of disease progression, ideally based on the EDSS, for which substantial experience exists. They should also include other motor and/or cognitive measures, for which less experience is available but which might have a higher sensitivity than the EDSS, enabling the capture of subtle but relevant changes in disability. The time periods used to determine the presence of CDP should be as long as practicable: 12 months, if possible. Neuroimaging outcomes should include traditional MRI measures such as those related to lesion load, as well as measures of brain atrophy. The inclusion of novel neuroimaging measures is encouraged, and their choice will probably depend on the mechanism of action of the drug or the specific research question that needs to be answered. In the clinic, the choice of response measures will guide decisions about treatment and patient management. Although use in the clinic of the same treatment response measures used in the trials that led to drug approval would be ideal, at present, most of the end points used in those trials cannot be used as response measures in the clinical setting. The technical, financial and logistical barriers to their clinical use include the time required to obtain these measures, the need for training and/or standardization and the fact that these measures have limited clinical rele vance at the individual patient level. Most importantly, validated cut-off values that predict a favourable outcome in the long term are lacking.
The use of PROMs and combined measures is important in both settings, as they capture the impact (and effects) of the intervention on clinical disability, MRI parameters, daily activities and quality of life. Further studies are needed to assess the reliability, accuracy and robustness of measures involving combinations of PROMs and objective (clinical and neuroimaging) parameters, which have the potential to comprehensively capture the intrinsic multidimensional nature of MS. Computation is slightly more complex than for new T2 or gadolinium-enhancing lesions (B)
Non-lesion-related MRI outcome measures
Brain-atrophy-related metrics (B) Reflect neurodegeneration, which is the most important substrate of disability accrual (B)
Susceptible to pseudo-atrophy phenomenon (B); high intra-individual (physiological) variation (B)
Spinal-cord-atrophy-related metrics (T) Reflect neurodegeneration in the spinal cord, which is highly related to motor disability (T)
Limited spatial resolution, which hampers multicentre studies (T); current segmentation methods are semi-automated, implying high inter-rater variability (T)
Novel imaging outcomes (MTR, NMR spectroscopy, diffusion-weighted imaging, PET-derived metrics) (T)
Provide information on microstructural features of brain damage, which is complementary to that given by lesion-related or atrophy-related measures (T)
Standardization of acquisition protocols and analysis methods is still in progress (T)
Optical coherence tomography (B)
• Provides information on axonal and neuronal loss within the anterior visual pathway, which is related to neurodegeneration (B) • Useful to monitor drug adverse effects, for example, of fingolimod (B)
Decreased reliability in patients with a history of optic neuritis (B)
Combined MRI and clinical outcomes, including NEDA (B)
NEDA is a comprehensive measure of real-life treatment effect (B)
• Difficult to interpret the net effect of drugs on the outcome measure (T) 
